Previous
Previous Product Image

American Academy of Neurology Annual On Demand 2019

30 $
Next

The Passmachine Internal Medicine Board Review 2018

20 $
Next Product Image

ERA-EDTA 58th ERA-EDTA Congress Symposia 2021

40 $

+ Include: 413 videos, size: 168 GB

+ Target Audience: nephrologist

Description

+ Include: 413 videos, size: 168 GB

+ Target Audience: nephrologist

+ Sample video: contact me for sample video

+ Topics:

A Look In Tge Crystal Ball Environment & Education – A STEP TOWARD GREEN NEPHROLOGY APPLYING THE PASSIVE HOUSE.mp4
A Look In Tge Crystal Ball Environment & Education – Achieving sustainable development goals in nephrology care, research and education 1.mp4
A Look In Tge Crystal Ball Environment & Education – Achieving sustainable development goals in nephrology care, research and education 2.mp4
A Look In Tge Crystal Ball Environment & Education – Nephrology education Looking to the Future.mp4
A Look In Tge Crystal Ball Environment & Education – WATER SAVING COMPARISON AT DIFFERENT DIALYSATE FLOWS IN EXPANDED HEMODIALYSIS.mp4
Acute Kidney Injury – AKI in COVID-19 patients What is new.mp4
Acute Kidney Injury – AKI in non-COVID disasters.mp4
Acute Kidney Injury – AKI in the obstetric clinics One complication, jeopardizing two lives.mp4
Acute Kidney Injury – Intrinsic renal AKI, but not acute tubular necrosis So what.mp4
Acute Kidney Injury – Management of severe AKI in the ICU the place of RRTs.mp4
AKI The Good, The Bad & The Ugly – AKI biomarkers as prognostic marker for development of CKD.mp4
AKI The Good, The Bad & The Ugly – COMPARISON OF THE CHARACTERISTICS AND MORTALITY OF ACUTE KIDNEY INJURY IN PATIENTS.mp4
AKI The Good, The Bad & The Ugly – INCIDENCE OF NOSOCOMIAL ACUTE KIDNEY INJURY (AKI) IN A COHORT OF COMMUNITY-DWELLING.mp4
AKI The Good, The Bad & The Ugly – IS AKI IN COVID-19 PATIENTS ASSOCIATED WITH INCREASED LENGTH OF STAY AND MORTALITY.mp4
AKI The Good, The Bad & The Ugly – URINARY LEVELS OF SARS-COV-2 NUCLEOCAPSID PROTEIN PREDICTS AKI AND FATAL OUTCOME IN COVID-19.mp4
Anaemia What Else – ENHANCED DEGRADATION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE.mp4
Anaemia What Else – POOLED EFFICACY AND CARDIOVASCULAR SAFETY RESULTS OF 3 PLACEBO-CONTROLLED.mp4
Anaemia What Else – POST-MORTEM HEPATIC AND BONE MARROW IRON CONTENT IN HEMODIALYSIS PATIENTS A PROSPECTIVE COHORT STUDY.mp4
Anaemia What Else – REGIONAL EFFICACY AND SAFETY RESULTS OF ROXADUSTAT COMPARED WITH PLACEBO.mp4
Anaemia What Else – THE SHORT-TERM IMPACT OF HIGH DOSE INTRAVENOUS IRON USE ON RENAL FUNCTION.mp4
Basic Science in AKI – Inflammatory cascade in acute kidney injury.mp4
Basic Science in AKI – IRF8 IN CDC1 IS PROTECTIVE IN POST-ISCHEMIC ACUTE KIDNEY INJURY.mp4
Basic Science in AKI – SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR (SUPAR) DETERMINES.mp4
Basic Science in AKI – THE LONG-TERM EFFECTS OF ACUTE KIDNEY INJURY ON INTESTINAL OXALATE-DEGRADING BACTERIA IN RATS.mp4
Basic Science in AKI – TUBULAR EPITHELIAL CELL POLYPLOIDY IS ESSENTIAL TO SURVIVE AKI BUT IT CONTRIBUTES.mp4
Basics & Clinics In Glomerulonephritis – CONTACTIN-1 IS A NOVEL ANTIGEN IN IDIOPATHIC MEMBRANOUS GLOMERULONEPHRITIS.mp4
Basics & Clinics In Glomerulonephritis – LARGE SCALE VALIDATION OF THE NEW INTERNATIONAL PROGNOSTIC SCORE OF IGA NEPHROPATHY.mp4
Basics & Clinics In Glomerulonephritis – Mesenchymal Stem Cell Therapy for Glomerulonephritis.mp4
Basics & Clinics In Glomerulonephritis – MicroRNA and kidney pathophysiology.mp4
Basics & Clinics In Glomerulonephritis – PODOCYTE AND GLOMERULAR ENDOTHELIAL CELL DERIVED MICRORNAS.mp4
Beat Autoimmunity – IPTACOPAN (LNP023) A NOVEL ORAL COMPLEMENT ALTERNATIVE PATHWAY FACTOR B INHIBITOR SAFELY.mp4
Beat Autoimmunity – LONG-TERM FOLLOW-UP OF PATIENTS WITH ANCA-ASSOCIATED VASCULITIS INCLUDED IN EUROPEAN.mp4
Beat Autoimmunity – SAFETY AND EFFICACY OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH LUPUS NEPHRITIS.mp4
Beat Autoimmunity – THE EFFECT OF AVACOPAN, A COMPLEMENT C5A RECEPTOR INHIBITOR, ON KIDNEY FUNCTION.mp4
Beat Autoimmunity – VOCLOSPORIN INCREASES RENAL RESPONSE AT COMMONLY USED UPCR THRESHOLDS IN PATIENTS WITH LUPUS NEPHRITIS.mp4
Big Data & Nephrology – CHRONIC KIDNEY DISEASE AND ATRIAL FIBRILLATION A DANGEROUS COMBINATION.mp4
Big Data & Nephrology – QUALITY OF LIFE OVER TIME IN OLDER MEN AND WOMEN WITH ADVANCED CKD RESULTS FROM THE EQUAL STUDY.mp4
Big Data & Nephrology – The analysis of large public databases for study of human disease the UK Biobank example.mp4
Big Data & Nephrology – USE OF POTENTIALLY NEPHROTOXIC MEDICATIONS IN PERSONS WITH CHRONIC KID NEY DISEASE.mp4
Big Data & Nephrology – WHEN TO INITIATE DIALYSIS TO REDUCE MORTALITY AND CARDIOVASCULAR EVENTS IN ADVANCED CKD.mp4
Bones & Outcomes In CKD – DIAGNOSTIC ACCURACY OF BONE TURNOVER MARKERS IN RENAL OSTEODYSTROPHY.mp4
Bones & Outcomes In CKD – HIGH SERUM PHOSPHATE, A NOVEL POTENTIAL RISK FACTOR FOR BONE FRAGILITY FRACTURES IN THE COSMOS STUDY.mp4
Bones & Outcomes In CKD – LONG-TERM SAFETY OF TENAPANOR FOR THE CONTROL OF SERUM PHOSPHORUS IN PATIENTS WITH CKD ON DIALYSIS.mp4
Bones & Outcomes In CKD – REAL-WORLD EFFECTIVENESS OF ETELCALCETIDE VS. CINACALCET IN US HEMODIALYSIS PATIENTS.mp4
Bones & Outcomes In CKD – VARIABILITY IN SERUM PHOSPHATE ASSESSED BY DIRECTIONAL CHANGE IS ASSOCIA- TED WITH INCREASED MORTALITY.mp4
Cells & Immunity – CKD DERIVED MUSCLE CELLS RETAIN PHENOTYPIC CHARACTERISTICS OF UREIC SARCOPENIA.mp4
Cells & Immunity – DEPOSITION OF PLATELET-DERIVED MICRO-PARTICLES IN PODOCYTES CONTRIBUTES TO DIABETIC NEPHROPATHY.mp4
Cells & Immunity – PHOSPHATE FACILITATES PHOSPHATURIA BY PIT-2-MEDIATED ACTIVATION OF ERK1 2 SIGNALLING.mp4
Cells & Immunity – PP2A PHOSPHATASE INHIBITION IS ANTI-FIBROTIC THROUGH SER77 PHOSPHORYLATION-MEDIATED.mp4
Cells & Immunity – Salt and immunity.mp4
CKD And Bone Mineral Disorders In CKD – Bone biopsy in clinical decision-making.mp4
CKD And Bone Mineral Disorders In CKD – Bone imaging and risk assessment in CKD.mp4
CKD And Bone Mineral Disorders In CKD – Bone turnover markers clinical utility in CKD.mp4
CKD And Bone Mineral Disorders In CKD – PTH, a troublesome hormone.mp4
Closing Session Nephrology Pearls – Basic Science and Translational Nephrology.mp4
Closing Session Nephrology Pearls – Epidemiology and Clinical Nephrology.mp4
Closing Session Nephrology Pearls – ESKD and Dialysis.mp4
Closing Session Nephrology Pearls – Kidney Transplantation.mp4
Cysts And Cancer – 4-WEEK ANTIBIOTIC THERAPY PREVENTS RECURRENT RENAL CYST INFECTIONS.mp4
Cysts And Cancer – Bardet-Biedle Syndrome from clinic to omics.mp4
Cysts And Cancer – CIRCULATING BIOMARKERS OF COLLAGEN TURNOVER ARE ASSOCIATED WITH DISEASE SEVERITY.mp4
Cysts And Cancer – INTERDEPENDENT REGULATION OF POLYCYSTIN EXPRESSION INFLUENCES STARVATION-INDUCED.mp4
Cysts And Cancer – Leveraging animal models for onconephrology research.mp4
Dialysis Heart & Vessels – BASELINE AND CORONARY ARTERY CALCIFICATION PROGRESSION MODULATES THE RISK OF DEATH.mp4
Dialysis Heart & Vessels – GLUCOSE DERIVATIVE INDUCED VASCULOPATHY IN CHILDREN ON PERITONEAL DIALYSIS.mp4
Dialysis Heart & Vessels – HIGHER MAGNESIUM DIALYSATE CONCENTRATION SIGNIFICANTLY IMPROVE SURVIVAL.mp4
Dialysis Heart & Vessels – PTH INDCUED ENDMT VIA MIR-29A-5P GSAP NOTCH1 PATHWAY CONTRIBUTED TO VALVULAR CALCIFICATION IN RATS WITH CKD.mp4
Dialysis Heart & Vessels – SNF472 ATTENUATES THE PROGRESSION OF FEMORAL ARTERY CALCIFICATION.mp4
Dialysis Nutrition & Outcomes – DIALYSIS WITHDRAWAL IN THE NETHERLANDS BETWEEN 2000-2020 TIME TRENDS AND CENTRE VARIATION.mp4
Dialysis Nutrition & Outcomes – HIGHER VARIABILITY OF SERUM PHOSPHATE IS ASSOCIATED WITH INCREASED MORTALITY.mp4
Dialysis Nutrition & Outcomes – Nutritional impact of HDF, a randomized trial.mp4
Dialysis Nutrition & Outcomes – TIME TRENDS IN PROBABILITY OF STARTING HOME DIALYSIS OVER A 20 YEAR PERIOD.mp4
Dialysis Nutrition & Outcomes – WEIGHT CHANGE AS A PREDICTOR OF MORTALITY IN CHRONIC HEMODIALYSIS PATIENTS.mp4
Dialysis Patterns Whats New – EFFICACY OF EXPANDED HEMODIALYSIS AT DIFFERENT DIALYSATE FLOWS.mp4
Dialysis Patterns Whats New – INCREASED VASCULAR REFILLING BY FEEDBACK-CONTROLLED ULTRAFILTRATION PROFILE.mp4
Dialysis Patterns Whats New – INTERMITTENT HEMODIALYSIS WITHOUT ANTICOAGULATION.mp4
Dialysis Patterns Whats New – THE EFFECT OF INCREMENTAL START OF HAEMODIALYSIS ON BLOOD PRESSURE.mp4
Dialysis Quality Of Life – Comprehensive Conservative Care what doctors say, what patients hear.mp4
Dialysis Quality Of Life – HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND SYMPTOM BURDEN.mp4
Dialysis Quality Of Life – LUNG ULTRASOUND-GUIDED ULTRAFILTRATION IN HAEMODIALYSIS PATIENTS REDUCES.mp4
Dialysis Quality Of Life – THE SOCIETAL IMPACT OF DELAYED DIALYSIS INITIATION ASSOCIATED WITH DAPAGLIFLOZIN.mp4
Dialysis Quality Of Life – UTILITY OF A SINGLE ITCH-RELATED QUESTION AND THE SKINDEX-10 QUESTIONNAIRE FOR ASSESSING.mp4
Electrolytes And Urolithiasis – Calcium and magnesium disorders.mp4
Electrolytes And Urolithiasis – Disorders of phosphate balance.mp4
Electrolytes And Urolithiasis – Hypo- and hyperparathyroidism.mp4
Electrolytes And Urolithiasis – Potassium.mp4
Electrolytes And Urolithiasis – Vasopressin and renal water handling.mp4
Fluid, GFR & CO. – ESTIMATING ALBUMIN TO CREATININE RATIO FROM PROTEIN TO CREATININE RATIO.mp4
Fluid, GFR & CO. – FUNCTIONAL SODIUM MAGNETIC RESONANCE IMAGING OF HUMAN KIDNEY.mp4
Fluid, GFR & CO. – Hydration and CKD Neither too much nor too little.mp4
Fluid, GFR & CO. – PERCENTILES OF NORMAL MEASURED GLOMERULAR FILTRATION RATE BASED ON DATA FROM LIVING KIDNEY DONORS.mp4
Fluid, GFR & CO. – RATIO OF MEASURED GFR TO ESTIMATED GFR MAY PREDICT EARLY DEATH AND REQUIREMENT FOR DIALYSIS.mp4
Fluid, GFR & CO. – SALIVARY POTASSIUM FOLLOWS PLASMA POTASSIUM DYNAMICS IN HEMODIALYSIS PATIENTS.mp4
Genes & Kidney – DEMONSTRATED COMPARABLE OXALATE REDUCTION AND SAFETY IN CHILDREN.mp4
Genes & Kidney – Epigenetic DNA and histone modifications for CKD treatment.mp4
Genes & Kidney – INFLUENCE OF GENETIC VARIATION IN SLC7A13 AGT1 IN HUMAN CYSTINURIA.mp4
Genes & Kidney – KIDNEYNETWORK USING KIDNEY DERIVED GENE EXPRESSION DATA TO PREDICT.mp4
Genes & Kidney – PRIMARY KIDNEY DISEASE IMPACTS OUTCOME IN CKD PREGNANCIES.mp4
Haemo- And Peritoneal Dialysis – Choice of dialysis mode and adapting prescriptions of PD and HD for patients with cirrosis and ascites.mp4
Haemo- And Peritoneal Dialysis – How can physicians improve AV fistula patency.mp4
Haemo- And Peritoneal Dialysis – Incremental dialysis in PD and HD.mp4
Haemo- And Peritoneal Dialysis – Rapid bedside testing for the diagnosis of PD peritonitis.mp4
Haemo- And Peritoneal Dialysis – Role of bioimpedance in aiding clinical decision on target weight (both for PD and HD).mp4
Hands-on Course On Renal Molecular Pathology – Indications, technical aspects and procedures of renal biopsy.mp4
Hands-on Course On Renal Molecular Pathology – Introduction to Molecular Renal Pathology.mp4
Hands-on Course On Renal Molecular Pathology – Practical aspects and procedures of renal biopsy.mp4
Hands-on Course On Renal Molecular Pathology – Review and discussion of 20 selected cases with virtual microscopy, immunofluorescence 1.mp4
Hands-on Course On Renal Molecular Pathology – Review and discussion of 20 selected cases with virtual microscopy, immunofluorescence 2.mp4
Hands-on Course On Renal Molecular Pathology – Review and discussion of 20 selected cases with virtual microscopy, immunofluorescence 3.mp4
Hands-on Course On Renal Molecular Pathology – Review and discussion of 20 selected cases with virtual microscopy, immunofluorescence 4.mp4
Hypertension & Omics – Fibromuscular dysplasia much more than a rare disease.mp4
Hypertension & Omics – HIGH DIETARY PHOSPHATE INTAKE UND INTRA-CARDIAC SYNTHESIS OF FIBROBLAST.mp4
Hypertension & Omics – PROTEOMIC PROFILING OF GLOMERULI FROM KIDNEYS WITH HYPERTENSIVE NEPHROPATHY.mp4
Hypertension & Omics – SINGLE CELL SEQUENCING REVEALS TRANSCRIPTIONAL SIGNATURES AND CELL.mp4
Hypertension & Omics – Sodium from gut microbiome to inflammation and hypertension.mp4
Hypertension, Diabetes, Cardiovascular Diseases In CKD – A death knell for supplemented Vitamin K to Improve Vascular Stiffness in CKD.mp4
Hypertension, Diabetes, Cardiovascular Diseases In CKD – Hyperkalemia in the new era of triple ACEARB and Finerenone no more a cause of concern.mp4
Hypertension, Diabetes, Cardiovascular Diseases In CKD – Is CV risk in CKD patients amplified by COVID-19.mp4
Hypertension, Diabetes, Cardiovascular Diseases In CKD – The role of non-invasive tools for assessing the cardiovascular risk of obese diabetic patients.mp4
Hypertension, Diabetes, Cardiovascular Diseases In CKD – Therapies for slowing the progression of diabetic kidney disease from renin angiotensin system.mp4
Interventions In CKD – AN OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFECTIVENESS.mp4
Interventions In CKD – EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSE IN PATIENTS WITH IRON DEFICIENCY.mp4
Interventions In CKD – Potassium and mortality.mp4
Interventions In CKD – SAFETY AND EFFICACY OF PATIROMER FOR HYPERKALAEMIA IN PATIENTS.mp4
Interventions In CKD – SAFETY OF BARDOXOLONE METHYL IN PEDIATRIC PATIENTS WITH ALPORT SYNDROME IN CARDINAL PHASE 3 TRIAL.mp4
KDIGO BP In CKD Controversial Guideline 2021 – BP measurement in the office Standardized measurement is vital and feasible Con.mp4
KDIGO BP In CKD Controversial Guideline 2021 – BP measurement in the office Standardized measurement is vital and feasible Pro.mp4
KDIGO BP In CKD Controversial Guideline 2021 – Lowering systolic BP in CKD to 120 mm Hg is reasonable Con.mp4
KDIGO BP In CKD Controversial Guideline 2021 – Lowering systolic BP in CKD to 120 mm Hg is reasonable Pro.mp4
Kidney Transplantation – How close are we to skip kidney biopsy and to diagnose kidney rejection with biomarkers.mp4
Kidney Transplantation – Recurrent glomerulonephritis following renal transplantation.mp4
Kidney Transplantation – Rejection episodes during COVID-19 pandemic Who to treat How to treat.mp4
Kidney Transplantation – Should we treat osteoporosis, hyperparathyroidism and hypercalcemia after kidney transplantation.mp4
Kids & Kidney – Diagnosis and management of nephrotic syndrome in children clinical practice guidelines from IPNA, ESPN and ERKNet.mp4
Kids & Kidney – HEMODIAFILTRATION IS ASSOCIATED WITH REDUCED INFLAMMATION AND INCREASED BONE.mp4
Kids & Kidney – OFATUMUMAB OR RITUXIMAB FOR CHILDREN WITH STEROID-DEPENDENT NEPHROTIC SYNDROME.mp4
Kids & Kidney – RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3B TRIAL OF TOLVAPTAN IN THE TREATMENT.mp4
Kids & Kidney – SHORT COURSE DAILY LOW-DOSE PREDNISOLONE AT THE TIME OF UPPER RESPIRATORY.mp4
Moderated Mini-Orals 4 – CALPROTECTIN IS A NOVEL CONTRIBUTING FACTOR IN VASCULAR CALCIFICATION AND A PREDICTOR.mp4
Moderated Mini-Orals 4 – CD47 BLOCKADE AMELIORATES AUTOIMMUNE VASCULITIS VIA THE EFFEROCYTOSIS OF NEUTROPHIL.mp4
Moderated Mini-Orals 4 – CLEARED PODOCYTES AND NORMAL KIDNEY FUNCTION IN CLASSICAL FABRY MALES 15 YEARS.mp4
Moderated Mini-Orals 4 – EFFECTS OF SHORT-TERM POTASSIUM CHLORIDE SUPPLEMENTATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE.mp4
Moderated Mini-Orals 4 – ESTIMATING THE BUDGET IMPACT OF DAPAGLIFLOZIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE.mp4
Moderated Mini-Orals 4 – HIGHLY SENSITIVE FLOW CYTOMETRIC DETECTION OF RESIDUAL B-CELLS AFTER RITUXIMAB.mp4
Moderated Mini-Orals 4 – KLOTHO AS A BIOMARKER OF SUBCLINICAL CARDIOVASCULAR DISEASE IN CHRONIC KIDNEY DISEASE.mp4
Moderated Mini-Orals 4 – NATURAL IMMUNISATION AGAINST ATHEROSCLEROSIS IN BEARS DURING HIBERNATION.mp4
Moderated Mini-Orals 4 – NON-AMYLOID TYPE OF MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE CLINICAL.mp4
Moderated Mini-Orals 4 – OUTCOME OF DIFFERENT INDUCTION REGIMENS IN ANCA-ASSOCIATED GLOMERULONEPHRITIS.mp4
Moderated Mini-Orals 4 – PREGNANCY OUTCOMES AND COMPLICATIONS IN PATIENTS WITH CHRONIC GLOMERULONEPHRITIS.mp4
Moderated Mini-Orals 4 – URINARY DICKKOPF-3 (UDKK3) A NEW BIOMARKER FOR LONG-TERM CKD PROGRESSION AND MORTALITY.mp4
Moderated Mini-Orals 4 – URINE METABOLITE LEVELS OF CKD PATIENTS ARE ASSOCIATED WITH ADVERSE KIDNEY OUTCOMES AND MORTALITY.mp4
Nephropathology – EMA ESOT consensus redefinition of rejection endpoints in kidney transplantation.mp4
Nephropathology – ERKNet consensus on obstructive uropathy renal dysplasia.mp4
Nephropathology – FSGS and minimal change glomerulopathy what can nephropathology contribute.mp4
Nephropathology – Nephropathology of Covid-19.mp4
Nephropathology – The spectrum of infection-associated glomerulonephritis.mp4
Outcomes in PD – Assisted PD strategies and outcomes.mp4
Outcomes in PD – CARDIAC GEOMETRY, FUNCTION, AND REMODELING PATTENRS AND LUNG WATER.mp4
Outcomes in PD – LITHIUM PRESERVES PERITONEAL MEMBRANE INTEGRITY BY REDUCING MESOTHELIAL CELL ├áB-CRYSTALLIN.mp4
Outcomes in PD – PD INDUCED ARTERIOLAR AND PERITONEAL PATHOMECHANISMS ARE PARTIALLY.mp4
Outcomes in PD – TOWARDS RAPID BEDSIDE TESTING FOR THE DIAGNOSIS OF PD-ASSOCIATED COMPLICATIONS.mp4
Pathology Meets Clinics – DEEP-LEARNING ENABLED QUANTIFICATION OF SINGLE-CELL SINGLE-MRNA TRANSCRIPTS.mp4
Pathology Meets Clinics – EXPERIMENTAL NEPHROTIC SYNDROME.mp4
Pathology Meets Clinics – SPARSENTAN IMPROVES GLOMERULAR BLOOD FLOW AND AUGMENTS PROTECTIVE TISSUE REMODELING.mp4
Pathology Meets Clinics – Update on diagnosis and therapy for non-AL amyloidosis.mp4
Pathophysiological Pathways In CKD – A RENAL-CARDIO INFLAMMATORY AXIS MEDIATES CARDIAC DYSFUNCTION IN CKD VIA IL-33-ST2.mp4
Pathophysiological Pathways In CKD – DAPAGLIFLOZIN DECREASES ALBUMINURIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE.mp4
Pathophysiological Pathways In CKD – DICKKOPF-3 (DKK3) LINKS RECIPROCAL LUNG AND KIDNEY INJURY IN MICE AND HUMANS.mp4
Pathophysiological Pathways In CKD – OBESITY AS A CAUSE OF KIDNEY DISEASE INSIGHTS FROM MENDELIAN RANDOMISATION STUDIES.mp4
Pathophysiological Pathways In CKD – PREDICTING OUTCOMES IN ANCA ASSOCIATED VASCULITIS THE COMPLETE SCOTTISH EXPERIENCE.mp4
Plants, Coffee & More – Coffee and mortality in CKD.mp4
Plants, Coffee & More – DIET QUALITY, PROTEIN-BOUND URAEMIC TOXINS AND GASTROINTESTINAL MICROBIOME IN CHRONIC KIDNEY DISEASE.mp4
Plants, Coffee & More – Plant based diets in CKD benefits and risks.mp4
Plants, Coffee & More – PROBIOTIC L.CASEI ZHANG SLOWS THE PROGRESSION OF ACUTE AND CHRONIC KID- NEY DISEASE.mp4
Plants, Coffee & More – ULTRA-PROCESSED FOOD CONSUMPTION AND RISK OF INCIDENT CHRONIC KIDNEY DISEASE.mp4
Plenary Lecture 1 – Development of novel, mechanism-based therapies for kidney diseases.mp4
Plenary Lecture 2 – A novel biological mechanism underlying renal cystogenesis and tumorigenesis.mp4
Plenary Lecture 3 – Integrating multiomics data for a better understanding of kidney disease.mp4
Prevention Of AKI – A RANDOMISED DOSE RANGING, PLACEBO-CONTROLLED, PHASE II STUDY ASSESSING THE EFFICACY.mp4
Prevention Of AKI – ACID-BASE BALANCE DURING IN-SERIES EXTRACORPOREAL CARBON DIOXIDE REMOVAL.mp4
Prevention Of AKI – AKI and cancer.mp4
Prevention Of AKI – PREDICTIVE VALUE OF PLASMA NGALHEPCIDIN-25 FOR MAJOR ADVERSE KIDNEY EVENTS AFTER CARDIAC SURGERY.mp4
Prevention Of AKI – THE PREDICTIVE ABILITY OF URINARY BIOMARKERS FOR PROGRESSION OF ACUTE KIDNEY INJURY IN CRITICAL ILLNESS.mp4
Primary & Secondary GN, Vasculitis And Autoimmune Diseases – Anti-GBM disease.mp4
Primary & Secondary GN, Vasculitis And Autoimmune Diseases – Immune-mediated interstitial nephritis.mp4
Primary & Secondary GN, Vasculitis And Autoimmune Diseases – Immune-mediated kidney disease and COVID-19.mp4
Primary & Secondary GN, Vasculitis And Autoimmune Diseases – Neutrophil extracellular traps in immune-mediated glomerular diseases.mp4
Primary & Secondary GN, Vasculitis And Autoimmune Diseases – Risk assessment for progression of IgA nephropathy.mp4
Protect The Membrane – ASSOCIATION OF SINGLE AND SERIAL MEASURES OF SERUM PHOSPHORUS WITH ADVERSE OUTCOMES.mp4
Protect The Membrane – DECLINING PERITONEAL HOST DEFENCES REVEALED BY EX-VIVO CYTOKINE RELEASE ASSAY.mp4
Protect The Membrane – MESENCHYMAL STEM CELL EXOSOMES AMELIORATE MICE PERITONEAL FIBROSIS INDUCED.mp4
Protect The Membrane – Mistakes we make in treating peritonitis.mp4
Protect The Membrane – PROTEOMIC PROFILE OF MESOTHELIAL EXOSOMES ISOLATED FROM PERITONEAL DIALYSIS.mp4
Stones and Brains – ACIDOSIS AND ALKALI THERAPY ARE ASSOCIATED WITH TRANSCRIPTIONAL CHANGES.mp4
Stones and Brains – Chronic Kidney Disease and Neurological Disorders Uremic Toxins as a piece of the incomplete puzzle.mp4
Stones and Brains – HYPERURICEMIA HAS VASOACTIVE EFFECTS IN CHOLESTEROL CRYSTAL-INDUCED ACUTE KIDNEY INJURY.mp4
Stones and Brains – Papal renal stone disease from Saint Peter to St. John Paul II.mp4
Stones and Brains – SERUM URIC ACID AND KIDNEY DISEASE MEASURES INDIPENDENTLY PREDICT CARDIOVASCULAR.mp4
Stop Diabetes – DUAL BLOCKADE OF ENDOTHELIN A RECEPTOR (ETA) AND SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT2).mp4
Stop Diabetes – GLOMERULI PROTEOME ANALYSIS REVEALS EARLY DIFFERENCES BETWEEN PRE-EXISTING.mp4
Stop Diabetes – LIPOTOXICITY MEDIATED BY GPR43 ACTIVATION CONTRIBUTES TO PODOCYTE INJURY IN DIABETIC NEPHROPATHY.mp4
Stop Diabetes – MIR-155 SOCS1 REGULATORY LOOP INFLUENCES DIABETIC KIDNEY DISEASE BY JAK STAT PATHWAY MODULATION.mp4
Stop Diabetes – SERUM INTERLEUKIN-6 LEVELS PREDICT RENAL DISEASE PROGRESSION IN DIABETIC KIDNEY DISEASE.mp4
Surviving CKD – CKD and prognosis, mortality, hospitalization.mp4
Surviving CKD – EARLY LIFE FACTORS AND ADULT KIDNEY FUNCTION ESTIMATED BY CYSTATIN C.mp4
Surviving CKD – METABOLIC PROFILING AS A MARKER OF CARDIOVASCULAR DISEASE AND ARTERIAL.mp4
Surviving CKD – OSTEOPONTIN AND ITS ASSOCIATION WITH ADVERSE EVENTS IN THE GERMAN CHRONIC KIDNEY DISEASE STUDY.mp4
Surviving CKD – THE IMPORTANCE OF ADDRESSING MULTIPLE RISK MARKERS IN TYPE 2 DIABETES.mp4
Symposium 0.1 Late Breaking Clinical Trials – A lung ultrasound guided treatment strategy (LUST) in end stage kidney disease patients at high cardiovascular risk.mp4
Symposium 0.1 Late Breaking Clinical Trials – Effects of Dapagliflozin on major adverse kidney events in patients with focal segmental glomerulosclerosis.mp4
Symposium 0.1 Late Breaking Clinical Trials – Interim analysis of a phase 2 dose ranging study to investigate the efficacy and safety of Iptacopan.mp4
Symposium 0.1 Late Breaking Clinical Trials – Orally administered C5AR inhibitor Avacopan in a randomized, double blind placebocontrolled study.mp4
Symposium 0.2 ERA-EDTA Registry – International comparison of trends in kidney transplantation rates in Europe.mp4
Symposium 0.2 ERA-EDTA Registry – Uraemic symptoms and uraemic toxins in the EQUAL study.mp4
Symposium 0.2 ERA-EDTA Registry – Work status and work ability of patients treated with kidney replacement therapy.mp4
Symposium 0.3 Hot Topics In Nephrology – Changes in the landscape of contrast nephropathy.mp4
Symposium 0.3 Hot Topics In Nephrology – New KDIGO guidelines on the management of glomerulonephritis.mp4
Symposium 0.3 Hot Topics In Nephrology – The role, use and pathophysiology of the complement system.mp4
Symposium 0.4 2021 Pearls Of NDT And CKJ – CKJ Editor selects 2 Speakers from the Editorial Board 1.mp4
Symposium 0.4 2021 Pearls Of NDT And CKJ – CKJ Editor selects 2 Speakers from the Editorial Board 2.mp4
Symposium 0.4 2021 Pearls Of NDT And CKJ – NDT Editor selects 2 Speakers from associate Editors 1.mp4
Symposium 0.4 2021 Pearls Of NDT And CKJ – NDT Editor selects 2 Speakers from associate Editors 2.mp4
Symposium 0.5 Avoiding A Crash Landing Of Nephrology By Creating Awareness – The burden of COVID-19 on the population with kidney disease.mp4
Symposium 0.5 Avoiding A Crash Landing Of Nephrology By Creating Awareness – The burden of kidney disease the unbearable lightness of neglect.mp4
Symposium 0.5 Avoiding A Crash Landing Of Nephrology By Creating Awareness – US Actions to Create Awareness on Kidney Disease and International Cooperation to Address Kidney Failure.mp4
Symposium 0.6 Future Scenarios For Renal Disease – Climate changes and nephrology.mp4
Symposium 0.6 Future Scenarios For Renal Disease – Demographic changes in different part of the world.mp4
Symposium 0.6 Future Scenarios For Renal Disease – Planetary health and burden of life style diseases what saves the planet saves our health.mp4
Symposium 0.7 Climate Change And Health The Opinion Of The Younger Generation – Global perspective on the climate crisis as a crisis of health.mp4
Symposium 0.7 Climate Change And Health The Opinion Of The Younger Generation – Perspectives for the coming medical generation regarding the climate crisis.mp4
Symposium 0.7 Climate Change And Health The Opinion Of The Younger Generation – Repercussions of heatwaves for kidney patients.mp4
Symposium 1.1 Acid-base Balance In Health And Kidney Disease – Acidosis in patients with kidney transplant origin and impact on outcome.mp4
Symposium 1.1 Acid-base Balance In Health And Kidney Disease – Alkali treatment and amelioration of kidney disease uncovering underlying mechanisms.mp4
Symposium 1.1 Acid-base Balance In Health And Kidney Disease – The renal response to acid(osis).mp4
Symposium 1.2 A New Look At Tubular Functions – How to build a tubular epithelium.mp4
Symposium 1.2 A New Look At Tubular Functions – Inherited defects of the proximal tubule reveal important pathways.mp4
Symposium 1.2 A New Look At Tubular Functions – Paracellular transport via claudins is essential for normal kidney function.mp4
Symposium 1.3 Phosphate And Other Minerals – Inhibition of intestinal and renal phosphate transport as new strategy to treat hyperphosphatemia in CKD.mp4
Symposium 1.3 Phosphate And Other Minerals – Phosphate and vascular calcification new avenues for treatment.mp4
Symposium 1.4 Electrolytes Renal Transport And Endocrine Control – Gender effects on tubular (salt) handling.mp4
Symposium 1.4 Electrolytes Renal Transport And Endocrine Control – Glucocorticoids and hypertension revisited.mp4
Symposium 1.4 Electrolytes Renal Transport And Endocrine Control – Renal potassium sensing and control of blood pressure.mp4
Symposium 2.1 Diagnosis And Treatment Of Rare Disease In Children And Adult CKD – Is ADPKD a paediatric disease.mp4
Symposium 2.1 Diagnosis And Treatment Of Rare Disease In Children And Adult CKD – Mendelian randomization reveals causative factors for kidney function impairment.mp4
Symposium 2.1 Diagnosis And Treatment Of Rare Disease In Children And Adult CKD – Treatment of patients with X-linked hypophosphatemia with borusumab advances and limitations.mp4
Symposium 2.2 Extracellular Vesicles And Kidney Diseases From Bio-markers To Therapeutic Bio-products – EVs as markersmediators of vascular ageing.mp4
Symposium 2.2 Extracellular Vesicles And Kidney Diseases From Bio-markers To Therapeutic Bio-products – Exosomes and microvesicles as biomarkers in renal physiology and diseases.mp4
Symposium 2.2 Extracellular Vesicles And Kidney Diseases From Bio-markers To Therapeutic Bio-products – Extracellular vesicles from urine and beyond.mp4
Symposium 2.3 Preeclampsia and kidney in 2021 – Endothelial dysfunction and activation in preeclampsia.mp4
Symposium 2.3 Preeclampsia and kidney in 2021 – Preeclampsia and future renal disease.mp4
Symposium 2.3 Preeclampsia and kidney in 2021 – Senescence and preeclampsia.mp4
Symposium 2.4 Networks And Registries In Rare Kidney Disease – ERKNet and its future perspectives.mp4
Symposium 2.4 Networks And Registries In Rare Kidney Disease – PKD registries.mp4
Symposium 2.4 Networks And Registries In Rare Kidney Disease – Registries in paediatric nephrology.mp4
Symposium 2.5 Updates On ADPKD – Imaging and genotyping to predict the outcome of ADPKD.mp4
Symposium 2.5 Updates On ADPKD – Metabolic reprogramming in ADPKD.mp4
Symposium 2.5 Updates On ADPKD – The role of chloride secretion in ADPKD.mp4
Symposium 2.6 An Integrated View Of ADTKD An Emerging Clinical And Genetic Entity – ADTKD-MUC1 from diagnostics to mechanisms.mp4
Symposium 2.6 An Integrated View Of ADTKD An Emerging Clinical And Genetic Entity – Cellular mechanisms, genotype to phenotype.mp4
Symposium 2.6 An Integrated View Of ADTKD An Emerging Clinical And Genetic Entity – Clinical and genetic spectra of ADTKD.mp4
Symposium 3.1 Covid-19 Pandemic – COVID-19 and history – a perspective from the great influenza pandemic of 1918.mp4
Symposium 3.1 Covid-19 Pandemic – COVID-19 in Europe – clinical experience and learnings.mp4
Symposium 3.1 Covid-19 Pandemic – COVID-19 trials Lessons for the future.mp4
Symposium 3.2 News In Glomerulonephritis Treatment – GWAS in glomerular diseases.mp4
Symposium 3.2 News In Glomerulonephritis Treatment – IgA nephropathy is immunosuppression needed.mp4
Symposium 3.2 News In Glomerulonephritis Treatment – Vasculitis and complement inhibition.mp4
Symposium 3.3 Membranous Nephropathy Insights From Recent Clinical Trials – Back to basics Cyclophosphamide steroids.mp4
Symposium 3.3 Membranous Nephropathy Insights From Recent Clinical Trials – Rituximab as first line therapy.mp4
Symposium 3.3 Membranous Nephropathy Insights From Recent Clinical Trials – The role of anti-PLA2R monitoring.mp4
Symposium 3.4 Onconephrology – Cancer immunotherapies (checkpoint inhibitors, CAR-T cells, IL-2) and the kidney.mp4
Symposium 3.4 Onconephrology – Haemathological disorders in transplant recipients.mp4
Symposium 3.4 Onconephrology – High cut-off filters and multiple myeloma.mp4
Symposium 3.5 Complicated lupus nephritis – Improved clarity of definitions and classification of glomerular lesions in lupus nephritis.mp4
Symposium 3.5 Complicated lupus nephritis – Management of refractory lupus nephritis.mp4
Symposium 3.5 Complicated lupus nephritis – Urinary exosomal miRNA expression profile in lupus nephritis.mp4
Symposium 3.6 ANCA vasculitis prognostic and treatment – ANCA vasculitis and treatment Where are we now.mp4
Symposium 3.6 ANCA vasculitis prognostic and treatment – Renal risk score for ANCA vasculitis.mp4
Symposium 3.6 ANCA vasculitis prognostic and treatment – Urinary CD163 in antineutrophil cytoplasm antibody-associated glomerulonephritis.mp4
Symposium 3.7 Kidney Stones – ABC of Randall’s plaques and stones from rare diseases to calcium nephrolithiasis.mp4
Symposium 3.7 Kidney Stones – From crystals to CKD.mp4
Symposium 3.7 Kidney Stones – Urate transporters, gout and urate nephropathy.mp4
Symposium 3.8 Up-to-date On Alport Syndrome – Linking basement membrane biology to glomerular disease.mp4
Symposium 3.8 Up-to-date On Alport Syndrome – New pathogenetic mechanisms and therapeutic implications.mp4
Symposium 3.8 Up-to-date On Alport Syndrome – Ongoing clinical trials.mp4
Symposium 3.9 The Nephrotoxicity Of Commonly Used Medications What Is The Evidence And What Are The Alternatives – Oral anticoagulants.mp4
Symposium 3.9 The Nephrotoxicity Of Commonly Used Medications What Is The Evidence And What Are The Alternatives – Paracetamol.mp4
Symposium 3.9 The Nephrotoxicity Of Commonly Used Medications What Is The Evidence And What Are The Alternatives – Proton pump inhibitors.mp4
Symposium 4.1 New treatment targets to halt CKD progression – Non-steroidal MRA – an emerging option.mp4
Symposium 4.1 New treatment targets to halt CKD progression – SGLT2-inhibition – the new standard.mp4
Symposium 4.1 New treatment targets to halt CKD progression – Targeting inflammation pathways – the future.mp4
Symposium 4.2 Microbiome in CKD – Exploring functional interactions between microbiota and host.mp4
Symposium 4.2 Microbiome in CKD – Microbiota in CKD how promising are gut-targeted approaches.mp4
Symposium 4.2 Microbiome in CKD – Personalized targeting of the microbiome.mp4
Symposium 4.3 Uraemic Toxicities – Uraemic toxins and endothelium.mp4
Symposium 4.3 Uraemic Toxicities – Uraemic toxins and macrophages.mp4
Symposium 4.3 Uraemic Toxicities – Uric acid and allopurinol in CKD a paradigm change.mp4
Symposium 4.4 CKD And Metabolic Disorders The Common Cognitive Outcome – Clinical testing for cognitive function in CKD patients.mp4
Symposium 4.4 CKD And Metabolic Disorders The Common Cognitive Outcome – Cognitive impairment and albuminuriahypertension.mp4
Symposium 4.4 CKD And Metabolic Disorders The Common Cognitive Outcome – Cognitive impairment in CKD.mp4
Symposium 4.5 Preventing Kidney Ageing – Non-genetic factors driving kidney ageing.mp4
Symposium 4.5 Preventing Kidney Ageing – Preserving Klotho expression.mp4
Symposium 4.5 Preventing Kidney Ageing – The potential influence of the genetic background.mp4
Symposium 4.6 New Nutritional Targets In CKD – Are low or very low protein diets still useful and attractive treatment in CKD.mp4
Symposium 4.6 New Nutritional Targets In CKD – Ketogenic diet a new tool to improve renal cyst growth in ADPKD.mp4
Symposium 4.6 New Nutritional Targets In CKD – Role of kidney proximal tubules to balance nutrient and uremic toxins levels.mp4
Symposium 4.7 SGLT2-Inhibitors In CKD Without Diabetes – How do SGLT2 inhibitors work.mp4
Symposium 4.7 SGLT2-Inhibitors In CKD Without Diabetes – Non-diabetic heart failure and CKD.mp4
Symposium 4.7 SGLT2-Inhibitors In CKD Without Diabetes – What does imaging tell us.mp4
Symposium 4.8 Randomized Trials – Slowing The Progression Of CKD – Clinical insight How should we use SGLT2 inhibitors in nephrology Discussion.mp4
Symposium 4.8 Randomized Trials – Slowing The Progression Of CKD – Clinical insight How should we use SGLT2 inhibitors in nephrology.mp4
Symposium 4.8 Randomized Trials – Slowing The Progression Of CKD – DAPA-CKD thinking beyond kidney disease.mp4
Symposium 4.8 Randomized Trials – Slowing The Progression Of CKD – FIDELIO-DKD – CV outcomes including atrial fibrillation 1.mp4
Symposium 4.8 Randomized Trials – Slowing The Progression Of CKD – FIDELIO-DKD – CV outcomes including atrial fibrillation 2.mp4
Symposium 4.8 Randomized Trials – Slowing The Progression Of CKD – FIDELIO-DKD – CV outcomes including atrial fibrillation 3.mp4
Symposium 4.8 Randomized Trials – Slowing The Progression Of CKD – FIDELIO-DKD – Renal efficacy & safety.mp4
Symposium 4.8 Randomized Trials – Slowing The Progression Of CKD – Summary.mp4
Symposium 4.8 Randomized Trials – Slowing The Progression Of CKD – The Big Three how RASi, SGLT2i & MRA.mp4
Symposium 4.8 Randomized Trials – Slowing The Progression Of CKD – The DAPA-CKD trial.mp4
Symposium 5.1 Non-dialysing In The 21st Century – Dialysis comorbidities and outcome.mp4
Symposium 5.1 Non-dialysing In The 21st Century – End of life in ESKD Complex decision interaction among the patient, the family and the nephrologist.mp4
Symposium 5.2 COVID-19 in haemodialysis patients – Infection control in dialysis units.mp4
Symposium 5.2 COVID-19 in haemodialysis patients – Outcomes in dialysis patients infected with SARS-CoV-2.mp4
Symposium 5.2 COVID-19 in haemodialysis patients – Prevention strategies for minimizing SARS-CoV-2 infection in dialysis facilities.mp4
Symposium 5.3 Innovations In Haemodialysis – How to reduce organ ischemia during haemodialysis can modern technologies help us.mp4
Symposium 5.3 Innovations In Haemodialysis – New haemodialysis therapies HDx therapy new membranes and others Do they mean any real improvement.mp4
Symposium 5.3 Innovations In Haemodialysis – The long journey towards a portable wearable dialysis What can we expect in the future.mp4
Symposium 5.4 Volume And Blood Pressure Control In Dialysis – Intradialytic hypertension an ignored killer.mp4
Symposium 5.4 Volume And Blood Pressure Control In Dialysis – The dialysis prescription for optimal volume control a KDIGO report.mp4
Symposium 5.4 Volume And Blood Pressure Control In Dialysis – The timing of Intradialytic hypotension.mp4
Symposium 5.5 Everyday Issues In Dialysis – How to choose the best sodium, potassium and bicarbonate level for an individual patient.mp4
Symposium 5.5 Everyday Issues In Dialysis – How to dose haemodialysis KtV, signs-symptoms, blood pressure, convection volume, so mething else.mp4
Symposium 5.5 Everyday Issues In Dialysis – How to incorporate patient related outcome measures into everyday dialysis care.mp4
Symposium 6.1 News In Peritoneal Dialysis – Biocompatible solutions and new osmotic agents.mp4
Symposium 6.1 News In Peritoneal Dialysis – Growth of peritoneal dialysis post-COVID-19.mp4
Symposium 6.1 News In Peritoneal Dialysis – Incremental peritoneal dialysis prescription.mp4
Symposium 6.2 Volume Control In Peritoneal Dialysis – Does bioimpedance have a role in volume control.mp4
Symposium 6.2 Volume Control In Peritoneal Dialysis – The anuric patient is there a space for weekly hypertonic solutions.mp4
Symposium 6.2 Volume Control In Peritoneal Dialysis – Which biomarkers should we use.mp4
Symposium 6.3 PD vs HD Similarities And Differences An Endless Debate – Regulation of central haemodynamics and blood pressure.mp4
Symposium 6.3 PD vs HD Similarities And Differences An Endless Debate – Sleep apnea and sleep quality in dialysis patients an emerging cardiovascular risk factor.mp4
Symposium 6.3 PD vs HD Similarities And Differences An Endless Debate – Technical methods for volume evaluation in ESKD.mp4
Symposium 7.1 Translational Research In Kidney Transplant From Bench To Beside – Cell-free DNA a valuable tool to monitor acute rejection after kidney transplantation.mp4
Symposium 7.1 Translational Research In Kidney Transplant From Bench To Beside – Genetic diagnostic biomarkers and new predictors of outcomes in kidney transplantation.mp4
Symposium 7.1 Translational Research In Kidney Transplant From Bench To Beside – T-cell exhaustion in kidney transplant recipients.mp4
Symposium 7.2 Recent advances in kidney transplantation focus on immunity – Immunologic monitoring and biomarkers in kidney transplant recipients.mp4
Symposium 7.2 Recent advances in kidney transplantation focus on immunity – NON-HLA Incompatibilities what’s new.mp4
Symposium 7.2 Recent advances in kidney transplantation focus on immunity – Targeting immuno-inflammation in kidney transplantation a new weapon against organ fibrosis.mp4
Symposium 7.3 Transplant Clinical Medicine – Deceased Donor-initiated Chains a way to avoid long waiting list.mp4
Symposium 7.3 Transplant Clinical Medicine – Graft loss in non adherent patients ethical challenges.mp4
Symposium 7.3 Transplant Clinical Medicine – Organ preservation and reconditioning- the dream comes true.mp4
Symposium 7.4 New Mechanisms Of Graft Damage In Kidney Transplantation – Inflammaging and complement system from acute kidney injury to chronic graft damage.mp4
Symposium 7.4 New Mechanisms Of Graft Damage In Kidney Transplantation – Machine perfusion optimizing the protocol for better preservation.mp4
Symposium 7.4 New Mechanisms Of Graft Damage In Kidney Transplantation – Preserving the donor new therapeutic approaches.mp4
Symposium 8.1 New Concepts In Cardiovascular Disease In CKD Patients – Blood-pressure insensitive arterial stiffness the major cardiovascular risk factor in ESRD.mp4
Symposium 8.1 New Concepts In Cardiovascular Disease In CKD Patients – The role of endothelial glycocalyx in health and disease.mp4
Symposium 8.1 New Concepts In Cardiovascular Disease In CKD Patients – Treatment of atrial fibrillation in patients with CKD a way between Scylla and Charybdis.mp4
Symposium 8.2 Diabetic nephropathy in 2021 – Beyond antidiabetic drugs for DKD what is new and upcoming.mp4
Symposium 8.2 Diabetic nephropathy in 2021 – How should future trials for DKD look like.mp4
Symposium 8.2 Diabetic nephropathy in 2021 – Nephroprotective antidiabetic drugs a prescription algorithm.mp4
Symposium 8.3 Hypertension treatment in special renal populations – Hypertension in children and adolescents in CKD.mp4
Symposium 8.3 Hypertension treatment in special renal populations – Hypertension in patients with renal transplantation current concepts and future directions.mp4
Symposium 8.3 Hypertension treatment in special renal populations – Hypertension management in transition from CKD to ESRD.mp4
Symposium 8.4 Kdigo Clinical Practice Guideline On Diabetes Management In CKD – HbA1c and beyond.mp4
Symposium 8.4 Kdigo Clinical Practice Guideline On Diabetes Management In CKD – Organ protection the new concept.mp4
Symposium 8.4 Kdigo Clinical Practice Guideline On Diabetes Management In CKD – Standard-of-care and self-management.mp4
Symposium 9.1 AKI In Special Situations – AKI a true risk or predictor of CKD.mp4
Symposium 9.1 AKI In Special Situations – AKI in oncology patients.mp4
Symposium 9.1 AKI In Special Situations – COVID-19 and AKI.mp4
Symposium 9.2 What Progress In AKI – AKI alerting systems, AI, biomarkers and imaging.mp4
Symposium 9.2 What Progress In AKI – AKI long-term consequences.mp4
Symposium 9.2 What Progress In AKI – AKI repair or regeneration what to target, when and how.mp4
Symposium 9.3 Endocannabinoids And Kidney – Cannabinoid receptor and hepatorenal syndrome.mp4
Symposium 9.3 Endocannabinoids And Kidney – From the endocannabinoid system to the endocannabinoidome.mp4
Symposium 9.3 Endocannabinoids And Kidney – The role of cannabinoid signalling in chronic kidney diseases.mp4
Symposium 9.4 New aspects in AKI prevention and treatment – ‘Subclinical’ AKI – does it matter.mp4
Symposium 9.4 New aspects in AKI prevention and treatment – Cost-effective prevention strategies for AKI.mp4
Symposium 9.4 New aspects in AKI prevention and treatment – New treatment options for AKI – does anything work.mp4
The Virus And The Kidney – ACID BASE DISORDERS IN COVID-19.mp4
The Virus And The Kidney – COVID-19 IMPACT ON ELDERLY HEMODIALYSIS POPULATION RESULTS FROM THE SPANISH.mp4
The Virus And The Kidney – COVID-19 IN PATIENTS ON KIDNEY REPLACEMENT THERAPY – CLINICAL CHARACTERISTICS.mp4
The Virus And The Kidney – COVID-19 RELATED MORTALITY IN KIDNEY TRANSPLANT AND DIALYSIS PATIENTS. A COMPARATIVE.mp4
The Virus And The Kidney – New data on transcriptomics and proteomics of COVID 19 in the kidney.mp4
Transplantation & New Technologies – Comprehensive Conservative Care what doctors say, what patients hear.mp4
Transplantation & New Technologies – Kidney allograft fibrosis what we have learned from latest translational research studies.mp4
Transplantation & New Technologies – MAGNETIC RESONANCE IMAGING TEXTURE ANALYSIS PREDICTS INTERSTITIAL FIBROSIS.mp4
Transplantation & New Technologies – SURVIVAL BENEFIT OF KIDNEY TRANSPLANTATION COMPARED TO REMAINING.mp4
Transplantation & New Technologies – THE UPTAKE OF PET RADIOTRACER 18 F-FLUORODEOXYGLUCOSE BY THE RENAL ALLOGRAFT.mp4
Transplantation Risk & Complications – BONE DENSITOMETRY IN RENAL TRANSPLANTED PATIENTS.mp4
Transplantation Risk & Complications – DIURETIC USE IS ASSOCIATED WITH INCREASED RISK FOR POSTTRANSPLANTATION DIABETES.mp4
Transplantation Risk & Complications – Kidney transplant suitability for patients with prior cancers what the nephrologist should know.mp4
Transplantation Risk & Complications – PATTERNS OF RENAL OSTEODYSTROPHY ONE YEAR AFTER KIDNEY TRANSPLANTATION.mp4
Transplantation Risk & Complications – RENAL TRANSPLANTATION MITIGATES INCREASED BIOLOGICAL (EPIGENETIC) AGE IN CHRONIC KIDNEY DISEASE.mp4
Transplantation Short- And Long-Term Outcomes – CHANGES IN PERIPHERAL NK CELLS IN KIDNEY TRANSPLANT RECIPIENTS.mp4
Transplantation Short- And Long-Term Outcomes – IMPACT OF POLYCLONAL ANTI-T-LYMPHOCYTE IMMUNOGLOBULINS ON THE RECURRENCE.mp4
Transplantation Short- And Long-Term Outcomes – NON-HLA ANTIBODIES AND EPLET MISMATCHES IN KIDNEY TRANSPLANT RECIPIENTS.mp4
Transplantation Short- And Long-Term Outcomes – Recurrent glomerulonephritis after kidney transplantation an update.mp4
Transplantation Short- And Long-Term Outcomes – SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS (SGLT2I) SHORT-TERM OUTCOME.mp4
Treat Diabetes – EFFECT OF GEMIGLIPTIN ON BIOMARKERS OF KIDNEY INJURY AND VASCULAR CALCIFICATION.mp4
Treat Diabetes – EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE ALBUMINURIA.mp4
Treat Diabetes – EFFECTS OF FINERENONE ON CARDIORENAL OUTCOMES IN BLOOD PRESSURE SUBGROUPS.mp4
Treat Diabetes – Renal histology in patients with type 2 diabetes the hidden role of vascular damage.mp4
Treat Diabetes – URINARY CCL5 MRNA, A POTENTIAL BIOMARKER FOR PROGRESSION OF TYPE 2 DIABETIC NEPHROPATHY.mp4
Treatment & Outcome Of Glomerulonephritis – C3 Glomerulopathy and Membranoproliferative Glomerulonephritis different diseases same treatment.mp4
Treatment & Outcome Of Glomerulonephritis – CRESCENTS DERIVE FROM SINGLE PODOCYTE PROGENITORS AND A DRUG ENHANCING.mp4
Treatment & Outcome Of Glomerulonephritis – INTERIM RESULTS OF PHASE 1 AND 2 TRIALS TO INVESTIGATE THE SAFETY, TOLERABILITY.mp4
Treatment & Outcome Of Glomerulonephritis – NEUTROPHILS PLAY A KEY ROLE ON THE INITIATION OF GLOMERULAR HEMATURIA IN A POSTINFECTIOUS.mp4
Treatment & Outcome Of Glomerulonephritis – RENAL OUTCOME AFTER RITUXIMAB IN ADULT-ONSET IGA VASCULITIS AND CRESCENTIC IGA NEPHROPATHY.mp4
WELCOME CEREMONY + WELCOME LECTURE 1.mp4
WELCOME CEREMONY + WELCOME LECTURE 2.mp4
WELCOME CEREMONY + WELCOME LECTURE 3.mp4
WELCOME CEREMONY + WELCOME LECTURE 4.mp4
WELCOME CEREMONY + WELCOME LECTURE 5.mp4
WELCOME CEREMONY + WELCOME LECTURE 6.mp4

Reviews

There are no reviews yet.

Be the first to review “ERA-EDTA 58th ERA-EDTA Congress Symposia 2021”

Your email address will not be published. Required fields are marked *